SCHEMBL645291

SCHEMBL645291

N#CC(=Cc1ccc(O)c(O)c1)C(=O)NCCCc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 14/20 1.00
MAPT P10636 6/20 1.00
KDM4E B2RXH2 5/20 1.00
MEN1 O00255 5/20 1.00
ALDH1A1 P00352 5/20 1.00
CYP3A4 P08684 5/20 1.00
HPGD P15428 5/20 1.00
ALOX15 P16050 5/20 1.00
ALOX12 P18054 5/20 1.00
MAPK1 P28482 5/20 1.00
RECQL P46063 5/20 1.00
BLM P54132 5/20 1.00
KMT2A Q03164 5/20 1.00
HSD17B10 Q99714 5/20 1.00
TDP1 Q9NUW8 5/20 1.00
SMN1; SMN2 Q16637 5/20 1.00
CYP1A2 P05177 4/20 1.00
TP53 P04637 4/20 1.00
NFKB1 P19838 4/20 1.00
PMP22 Q01453 4/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL645290 1.00 EGFR (1.00) EGFRMAPTKDM4EMEN1ALDH1A1
SCHEMBL29378814 1.00 EGFR (1.00) EGFRMAPTKDM4EMEN1ALDH1A1
SCHEMBL29376415 0.97 EGFR (1.00) EGFRMAPTKDM4EMEN1ALDH1A1
SCHEMBL3486952 0.97 EGFR (1.00) EGFRMAPTKDM4EMEN1ALDH1A1
SCHEMBL2533402 0.97 EGFR (1.00) EGFRMAPTKDM4EMEN1ALDH1A1
SCHEMBL6055311 0.97 EGFR (1.00) EGFRMAPTKDM4EMEN1ALDH1A1
SCHEMBL7378564 0.93 EGFR (1.00) EGFRMAPTKDM4EMEN1ALDH1A1
SCHEMBL6599706 0.90 EGFR (0.82) EGFRMAPTKDM4EMEN1ALDH1A1
SCHEMBL6599711 0.90 EGFR (0.82) EGFRMAPTKDM4EMEN1ALDH1A1
SCHEMBL30274781 0.90 EGFR (0.82) EGFRMAPTKDM4EMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150274633-A2 PAIN RELIEF COMPOUNDS UNIVERSITÉ CLERMONT AUVERGNE (FR) 2015-10-01 US claimed
US-20150038466-A1 PAIN RELIEF COMPOUNDS ECOLE NATIONALE SUPERIEURE DE CHIMIE DE CLERMONT FERRAND (FR) 2015-02-05 US claimed
EP-2797886-A2 PAIN RELIEF COMPOUNDS Ecole Nationale Superieure de Chimie de Clermont Ferrand (FR) 2014-11-05 EP claimed
WO-2013098416-A2 PAIN RELIEF COMPOUNDS ECOLE NATIONALE SUPERIEURE DE CHIMIE DE CLERMONT FERRAND (FR) 2013-07-04 WO claimed
EP-2164329-A2 TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION The Burnham Institute for Medical Research (US) 2010-03-24 EP claimed
US-20090156560-A1 TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE 2009-06-18 US claimed
WO-2009017863-A2 TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2009-02-05 WO claimed
EP-1156775-B1 REDUCTION OF HAIR GROWTH GILLETTE CO (US) 2006-05-17 EP claimed
EP-1156775-A1 REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 2001-11-28 EP claimed
US-6121269-A TOPICALLY APPLYING A PROTEIN-TYROSINE KINASE INHIBITOR TO SKIN TO REDUCE ANDROGEN-STIMULATED HAIR GROWTH WITHOUT SIDE EFFECTS GILLETTE COMPANY, THE, A DELAWARE CORPORATION 2000-09-19 US claimed
WO-2000050002-A1 REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 2000-08-31 WO claimed
EP-4578457-A1 PHARMACEUTICAL FOR TREATING AND/OR PREVENTING CANCER Toray Industries, Inc. (JP) 2025-07-02 EP disclosed
US-12295955-B2 TTP phosphorylation for the identification of personalized medicines KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) 2025-05-13 US disclosed
CN-119768182-A Medicine for treating and/or preventing cancer 东丽株式会社 2025-04-04 CN disclosed
US-20240390406-A1 PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTIAGING DRUGS KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) 2024-11-28 US disclosed
EP-1156775-B1 REDUCTION OF HAIR GROWTH GILLETTE CO (US) 2006-05-17 EP disclosed
EP-1156775-A1 REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 2001-11-28 EP disclosed
US-6121269-A TOPICALLY APPLYING A PROTEIN-TYROSINE KINASE INHIBITOR TO SKIN TO REDUCE ANDROGEN-STIMULATED HAIR GROWTH WITHOUT SIDE EFFECTS GILLETTE COMPANY, THE, A DELAWARE CORPORATION 2000-09-19 US disclosed
WO-2000050002-A1 REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 2000-08-31 WO disclosed
WO-1997023202-A1 SUBTYPE-SELECTIVE NMDA RECEPTOR LIGANDS AND THE USE THEREOF STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITYA ND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) 1997-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038466-A1 PAIN RELIEF COMPOUNDS OPRL1, OPRK1, TRPV1 EGFR 4863/4885MAPT 2966/4885KDM4E 3622/4885
US-20090156560-A1 TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION ALPL, CNDP2, ALPI EGFR 3957/4885MAPT 3950/4885KDM4E 1913/4885
US-20150274633-A2 PAIN RELIEF COMPOUNDS OPRL1, OPRK1, TRPV1 EGFR 4863/4885MAPT 2966/4885KDM4E 3622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.